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758respectively), although the curves did not diverge
until well after 24 months, the maximum duration of
follow-up reported by THAOS investigators.
We believe our single-center data, although smaller
in numbers, have the advantage of a closer follow-up
for a longer period of time, with the potential to have
received a more uniform standard of care. Our obser-
vation of a significantly shorter survival of patients
with mt-ATTR due to the Val122Ile mutation strongly
suggests that Val122Ile ATTR cardiac amyloidosis is a
more aggressive disease than wild-type ATTR and ar-
gues for caution not only in interpreting multisite
database data but also when considering the design of
future studies of ATTR cardiac amyloidosis in which
both mutant and wild-type patients are enrolled.Avinainder Singh, MBBS
Hallie I. Geller, BS
*Rodney H. Falk, MD
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ent in THAOS over 3 years (A: overall survival in which 36-month estimate 
age-adjusted hazard ratio for Val122Ile versus Wild-type ¼ 1.947; Wald chi-R EF E RENCE
1. Maurer MS, Hanna M, Grogan M, et al., and Investigators. Genotype and
phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amy-
loid Outcome Survey). J Am Coll Cardiol 2016;68:161–72.REPLY: Val122Ile mt-ATTR Has a Worse
Survival Than wt-ATTR Cardiac AmyloidosisDr. Singh and colleagues present single-center data
that demonstrate a worse survival among subjects
with transthyretin cardiac amyloid (ATTR) cardiac
amyloid due to the Val122Ile mutation than that of
those with wild-type ATTR (wt-ATTR), with differ-
ences emerging after 2 years of follow-up. Such data
are consistent with those of other single-center re-
ports (1), as well as the small multicenter TRACS
(Transthyretin Amyloidosis Cardiac Study) study (2)
in 29 subjects, but differ from data reported in in-
ternational multicenter THAOS (Transthyretin Amy-
loid Outcome Survey) in a larger cohort (3). In THAOS,
survival from time of enrollment rather than survival
from diagnosis was reported as defining onset of the
disease retrospectively, which is difficult given the
association of ATTR cardiac amyloid with common
age-related conditions. Concerns were raised about
the completeness of follow-up, and we acknowledged
that this could confound our reported results.
Prompted by the analyses of Singh and colleagues, we
evaluated survival from enrollment in THAOS over0
Time from Enrollment (Months)
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Wild–type Val122Ile
SE is 47.5%  6.1% for Wild-type and 55.1%  8.0% for Val122Ile)
square p value ¼ 0.0132).
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7593 years and found that, although overall survival still
did not differ between wt-ATTR and Val122Ile
(Figure 1A), age-adjusted survival was worse for
Val122Ile patients than for wt-ATTR patients
(Figure 1B). Such data would support stratifying
enrollment of future clinical trials by mutation status.
Perhaps most importantly, if there are differences
between outcomes for American black patients with
ATTR cardiac amyloidosis due to the Val122Ile muta-
tion and those of Caucasians with the wild-type ATTR
amyloidosis, which are phenotypically similar, we
need to understand if these differences are due to
nature (e.g., the presence of a mutation) or nurture
(e.g., disparities related to access to care). Indeed, we
are particularly troubled by the observation that
American black patients present with more advanced
disease than Caucasians with ATTR cardiac amyloid
(4), despite having a noninvasive method for early
identification (genetic testing). Further research to
determine if this is the result of inadequate access to
care or has a biological basis is warranted.*Mathew S. Maurer, MD
Rajiv Mundayat, MS
Claudio Rapezzi, MD*Columbia University Medical Center
ClinicalCardiovascularResearchLaboratory for theElderly
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